INTRODUCTION
============

Clear cell renal cell carcinoma (RCC) is the most common histological subtype of adult kidney cancer ([@b28]). In general, RCCs at an early stage are curable by nephrectomy. However, some RCCs relapse and metastasize to distant organs. Even though molecular targeting agents have been developed for treatment of RCCs, their effectiveness for relapsed or metastasized RCCs after nephrectomy is very limited. To improve prognostication and the effectiveness of targeting therapy in patients with RCCs, the molecular background of renal carcinogenesis should be further elucidated.

We and other groups have revealed both genetic and epigenetic events during renal carcinogenesis ([@b1]). Especially, recent developments in high-throughput sequence capture methods and next-generation sequencing technologies have made exome sequencing technically feasible. Such whole exome analyses have revealed that renal carcinogenesis involves inactivation of histone-modifying genes such as *SETD2* ([@b10]), *KDM5C* ([@b10]), *UTX* ([@b47]), and *PBRM1* ([@b48]). Moreover, it is well known that clear cell RCCs are characterized by inactivation of the *VHL* tumor suppressor gene encoding a component of the protein complex that possesses ubiquitin ligase E3 activity ([@b3]). Frequent mutation of a further component of the ubiquitin-mediated proteolysis pathway gene, *BAP1* ([@b17]), and *VHL*-associated transcription elongation factor, *TCEB1* ([@b38]), has also been demonstrated on the basis of exome analyses. However, only a limited number of reports have described next-generation sequencing-based whole transcriptome analysis (RNA sequencing) of RCCs, and the molecular background of renal carcinogenesis has not been fully elucidated.

Human hematologic ([@b39]) and soft tissue malignancies ([@b6]), prostatic adenocarcinoma ([@b46]), and distinct subtypes of lung adenocarcinoma ([@b41]; [@b22]; [@b43]) show "addiction" for gene fusion events. Although their incidence is low, fusion events involving the transcription factor *TFE3* gene have been reported in RCCs: RCC associated with Xp11.2 translocation, which harbors *TFE3* fusion, is considered to represent a distinct subtype according to the World Health Organization (WHO) classification ([@b13]). Moreover, fusion events including anaplastic lymphoma kinase (*ALK*), such as *TMP3-ALK*, *EML4-ALK*, and *VCL-ALK* fusion, have been reported in a distinct group of RCCs, including so-called "unclassified RCC" and papillary RCC in adults ([@b42]) and pediatric RCCs associated with the sickle cell trait ([@b12]; [@b30]), based on fluorescence in situ hybridization (FISH) and immunohistochemistry. These findings have prompted us to perform comprehensive exploration of chimeric transcripts in the most common subtype, clear cell RCC, using next-generation sequencing technology. In the present study, to clarify the participation of expression of chimeric transcripts in renal carcinogenesis, whole transcriptome analysis was performed using tissue specimens of 68 clear cell RCCs in adults.

MATERIALS AND METHODS
=====================

Patients and Tissue Samples
---------------------------

The initial cohort subjected to whole transcriptome analysis comprised 68 samples of cancerous tissue (T) and 11 samples of non-cancerous renal cortex tissue (N) obtained from materials that had been surgically resected from 68 patients with primary clear cell RCCs. There were 49 men and 19 women with a mean (±standard deviation) age of 62.3 ± 11.0 years (range, 36 to 85 years). All patients underwent nephrectomy at the National Cancer Center Hospital, Tokyo, and had not received any preoperative treatment. Two expert pathologists specializing in genitourinary pathology, E.A. and Y.K., examined all histological slides and performed histological diagnosis in accordance with the WHO classification ([@b13]). All the tumors were graded on the basis of previously described criteria ([@b14]) and classified according to the macroscopic configuration ([@b2]) and the pathological Tumor-Node-Metastasis (TNM) classification ([@b40]). As a positive control for chimeric transcript detection, two T samples showing histological findings compatible with Xp11.2 translocation RCC based on the WHO criteria were also subjected to whole transcriptome analysis. For comparison, three T samples of papillary RCCs diagnosed in accordance with the WHO criteria were also subjected to whole transcriptome analysis.

The second cohort subjected to quantitative reverse transcription-polymerase chain reaction (RT-PCR) analysis comprised 26 paired T and N samples obtained from materials that had been surgically resected from 26 other patients with primary clear cell RCCs. These patients comprised 17 men and nine women with a mean (±standard deviation) age of 57.1 ± 10.8 years (range, 33--81 years). Copy number analysis using the HumanOmni1-Quad BeadChip (Illumina, San Diego, CA) and Global Parameter Hidden Markov Model (<http://bioinformatics.ustc.edu.cn/gphmm/>; [@b25]) revealed copy number alterations in chromosome 3 in all 91 clear cell RCCs in the initial and second cohorts (with three exceptions, Supporting Information Tables S1 and S2 and Supporting Information Fig. S1). These findings were considered to be the hallmark of clear cell RCCs in the initial and second cohorts. The clinicopathological parameters of RCCs belonging to the initial and second cohorts are summarized in Table[1](#tbl1){ref-type="table"}.

###### 

The Clinicopathological Parameters of Clear Cell Renal Carcinomas Belonging to the Initial and Second Cohorts

  Clinicopathological parameters                                    Initial cohort (*n* = 68)   Second cohort (*n* = 26)   *P*
  ----------------------------------------------------------------- --------------------------- -------------------------- ---------------------------------------
  Age (mean ± SD)                                                   62.25 ± 11.00               57.12 ± 10.80              0.078[a](#tf1-1){ref-type="table-fn"}
  Sex                                                                                                                      
   Male                                                             49                          17                         0.616[b](#tf1-2){ref-type="table-fn"}
   Female                                                           19                          9                          
  Tumor diameter (cm, mean ± SD)                                    5.55 ± 3.21                 5.86 ± 2.84                0.407[a](#tf1-1){ref-type="table-fn"}
  Macroscopic configuration[c](#tf1-3){ref-type="table-fn"}                                                                
   Type 1                                                           25                          13                         0.562[b](#tf1-2){ref-type="table-fn"}
   Type 2                                                           17                          5                          
   Type 3                                                           26                          8                          
  Predominant histological grades[e](#tf1-5){ref-type="table-fn"}                                                          
   G1                                                               36                          12                         0.696[b](#tf1-2){ref-type="table-fn"}
   G2                                                               21                          8                          
   G3                                                               9                           4                          
   G4                                                               2                           2                          
  Highest histological grades[f](#tf1-6){ref-type="table-fn"}                                                              
   G1                                                               5                           1                          0.105[b](#tf1-2){ref-type="table-fn"}
   G2                                                               32                          6                          
   G3                                                               16                          11                         
   G4                                                               15                          8                          
  Vascular involvement[g](#tf1-7){ref-type="table-fn"}                                                                     
   Negative                                                         38                          13                         0.649[b](#tf1-2){ref-type="table-fn"}
   Positive                                                         30                          13                         
  Predominant growth pattern[e](#tf1-5){ref-type="table-fn"}                                                               
   Expansive                                                        61                          24                         1.000[b](#tf1-2){ref-type="table-fn"}
   Infiltrative                                                     7                           2                          
  Most aggressive growth pattern[f](#tf1-6){ref-type="table-fn"}                                                           
   Expansive                                                        43                          21                         0.139[b](#tf1-2){ref-type="table-fn"}
   Infiltrative                                                     25                          5                          
  Tumor necrosis                                                                                                           
   Negative                                                         51                          16                         0.212[b](#tf1-2){ref-type="table-fn"}
   Positive                                                         17                          10                         
  Renal pelvic invasion                                                                                                    
   Negative                                                         61                          23                         1.000[b](#tf1-2){ref-type="table-fn"}
   Positive                                                         7                           3                          
  Distant metastasis                                                                                                       
   Negative                                                         58                          24                         0.500[b](#tf1-2){ref-type="table-fn"}
   Positive                                                         10                          2                          
  Pathological TNM stage[h](#tf1-8){ref-type="table-fn"}                                                                   
   Stage I                                                          33                          13                         0.531[b](#tf1-2){ref-type="table-fn"}
   Stage II                                                         4                           3                          
   Stage III                                                        19                          8                          
   Stage IV                                                         12                          2                          

Mann--Whitney *U* test.

Fisher\'s exact test. No significant differences of clinicopathologcial parameters were observed between two cohorts.

Macroscopic configuration was evaluated on the basis of previously described criteria ([@b2]).

All the tumors were graded on the basis of previously described criteria ([@b14]).

If the tumor showed heterogeneity, findings in the predominant area were described.

If the tumor showed heterogeneity, the most aggressive features of the tumor were described.

The presence or absence of vascular involvement was examined microscopically on slides stained with hematoxylin-eosin and elastica van Gieson.

All the tumors were classified according to the pathological Tumor-Node-Metastasis classification ([@b40]).

Tissue specimens were taken and frozen immediately after surgical removal, and thereafter stored in liquid nitrogen until use. These tissue specimens were provided by the National Cancer Center Biobank, Tokyo. This study was approved by the Ethics Committees of the National Cancer Center and National Center for Global Health and Medicine, Tokyo, and was performed in accordance with the Declaration of Helsinki. All the patients provided written informed consent prior to inclusion in the study.

Whole Transcriptome Analysis
----------------------------

Total RNA was isolated using TRIzol reagent (Life Technologies, Carlsbad, CA). A total of 84 (73 T and 11 N) samples in the initial cohort were subjected to whole transcriptome analysis. Sequencing libraries were prepared from 1.0 to 2.5 μg of total RNA using an mRNA-Seq Sample Prep Kit or a TruSeq RNA Sample Prep Kit (Illumina), according to the manufacturer\'s standard protocols. An mRNA-Seq Sample Prep Kit was used for libraries of 35 (30 T and 5 N) samples, and these libraries were prepared using a procedure including a gel purification step, in which a fraction of 250--300 bp (insert size: 150--200 bp) was collected. A TruSeq RNA Sample Prep Kit was used for libraries of the other 49 (43 T and 6 N) samples, and these libraries were prepared without gel purification. The resulting libraries were subjected to paired-end sequencing of 50-base reads on a GAIIx or HiSeq2000 sequencer (Illumina).

Detection of Chimeric Transcripts
---------------------------------

To avoid multiple counting of each chimeric transcript, RNA sequencing data were used after removal of paired-end reads with the identical nucleotide sequence, which had probably been derived from PCR duplicates during library preparation. For prediction of chimeric transcripts, the deFuse program version 0.4.3 was used ([@b33]). After applying default filtering of this program, potential alternative splicing and read-through products that the program predicted were eliminated, and candidates that had exon boundary junctions were selected. Finally, we discarded candidates that were also predicted from the data of 11 N samples.

RT-PCR and Sanger Sequencing
----------------------------

cDNA was reverse-transcribed from the total RNA (500 ng) of the initial cohort samples, in which candidate chimeric transcripts were detected by whole transcriptome analysis, using random primers and Superscript III RNase H^−^Reverse Transcriptase (Life Technologies). cDNA (corresponding to 10 ng total RNA) was subjected to PCR amplification using an optimal DNA polymerase among AmpliTaq Gold DNA Polymerase (Life Technologies), HotStar Taq DNA polymerase (Qiagen, Hilden, Germany) or KAPA Taq DNA Polymerase (KAPA Biosystems, Woburn, MA). The PCR products were separated electrophoretically on 2% agarose gel and stained with ethidium bromide to confirm that specific products of the size estimated on the basis of whole transcriptome analysis were obtained, and that no nonspecific products appeared on amplification. The PCR products were then directly sequenced in both directions using the same primers with the BigDye Terminator v3.1 Cycle Sequencing kit and an ABI 3130xl DNA Sequencer (Life Technologies).

Genomic PCR and Sanger Sequencing
---------------------------------

High-molecular-weight genomic DNA was extracted from the initial cohort samples, in which candidate chimeric transcripts were verified by the above RT-PCR and Sanger sequencing, using phenol--chloroform followed by dialysis. Genomic DNA (10 ng) was subjected to PCR amplification using an optimal DNA polymerase among AmpliTaq Gold DNA Polymerase, Platinum Taq DNApolymerase high fidelity (Life Technologies), HotStar Taq DNA polymerase (Qiagen) or KAPA Taq DNA Polymerase (KAPA Biosystems). The PCR products were separated electrophoretically on 1% agarose gel and stained with ethidium bromide to confirm that no nonspecific products appeared on amplification. The PCR products were then directly sequenced in both directions using the same primers with the BigDye Terminator v3.1 Cycle Sequencing kit and an ABI 3130xl DNA Sequencer (Life Technologies).

Quantitative RT-PCR Analysis
----------------------------

cDNA was reverse transcribed from total RNA (500 ng) of the 26 paired T and N samples of the second cohort using random primers and Superscript III RNase H^−^Reverse Transcriptase (Life Technologies). mRNA expression was analyzed using custom TaqMan Gene Expression Assays and TaqMan Fast Advanced Master Mix (Life Technologies) on a 7500 Fast Real-Time PCR System (Life Technologies) employing the relative standard curve method. Experiments were performed in triplicate for each sample-primer set, and the mean value for the three experiments was used as the CT value. All CT values were normalized to that of *GAPDH* in the same sample.

Statistics
----------

Differences in clinicopathological parameters between the initial and second cohorts were assayed by Mann--Whitney *U* test and Fisher\'s exact test. Differences in the levels of mRNA expression between N and T samples were examined by Mann--Whitney *U* test. Correlations between levels of mRNA expression and clinicopathological parameters were assayed by Kruskal--Wallis test and Mann--Whitney *U* test. Receiver operating characteristic (ROC) curves were generated for the levels of mRNA expression of each partner gene involved in the chimeric transcripts, and the thresholds were set at the top left corner of the graph. Subsequently, the impact of chimeric transcript expression and downregulation of mRNA levels for each partner gene on patient outcome was analyzed by the Kaplan--Meier method using the set thresholds and the log-rank test. Differences at *P* \< 0.05 were considered to be significant.

RESULTS
=======

Identification of Novel Chimeric Transcripts in RCCs of the Initial Cohort
--------------------------------------------------------------------------

We performed RNA sequencing of 68 T samples (K1 to K68) and 11 N samples in the initial cohort, and a T sample (K69) showing histological findings compatible with Xp11.2 translocation RCC. At least 30,000,000 reads (average read count 50,000,000) were obtained for each sample. The deFuse program version 0.4.3 ([@b33]) provided 3,746 fusion gene candidates from the data obtained using the 69 T samples by applying default filtering. From those candidates, 95 were extracted by eliminating potential alternative splicing and read-through products that the program predicted, and by selecting candidates that had exon boundary junctions. Next, candidates that were predicted even from the data obtained using the 11 N samples were discarded, and finally 35 candidates were obtained. Three candidates were abandoned because of difficulty with the primer design and shortage of samples, and then RT-PCR analysis was performed for the 32 candidates in the same T sample. The PCR and sequencing primers used are shown in Supporting Information Table S3.

After a T sample (K96) of Xp11.2 translocation RCC and three T samples of papillary RCCs (K97 to K99) had been additionally analyzed for comparison, expression of 33 fusion transcripts (including two transcripts \[*MMACHC-BX004987.7* and *TFE3-RBM10*\] consisting of the same partner gene sets with a different exon boundary or a different transcriptional direction and three transcripts sharing a partner gene, *TFE3*) from the 61 genes was finally verified by RT-PCR, and the exon boundaries and flanking sequences were determined by Sanger sequencing analysis (Table[2](#tbl2){ref-type="table"} and Supporting Information Fig. S2).

###### 

The 33 Chimeric Transcripts[a](#tf2-1){ref-type="table-fn"} from the 61 Genes Verified by Reverse Transcription-PCR and Sanger Sequencing

                                           Exon boundaries[b](#tf2-2){ref-type="table-fn"}                                                                                                                                                                                                                            
  ------------------------- -------------- ------------------------------------------------- -------------- ---------------------- ---------------------- -------------- ---------------------------------------------------------------- ---------- ---------------------------------------------------------------- ----
  \(A\) Initial cohort                                                                                                                                                                                                                                                                                                
   Clear                    K1             *ANTXR1*                                          NM_032208      17 (ch 2, 69420547)    *GKN1*                 NM_019617      2 (ch 2, 69204627)                                               215920     TCTGTGATGCGTCCACAGCCAGGAGACACG\|ATCGTCTTTGCTGGACTTCTTGGAGTCTTT   \+
  *B4GALT2*                 NM_001005417   3 (ch 1, 44450537)                                *ZSWIM5*       NR_024270              1 (ch 1, 45769599)     1319062        CTTGGCCCGGTTGAAGGTGTCCTCACCATG\|GGTTTCGGAGTAAGGGGAGCGGCCCGGCGA   −                                                                           
  *C9orf3*                  NM_001193329   12 (ch 9, 97767898)                               *PRUNE2*       NM_015225              19 (ch 9, 79229516)    18538382       CGCAGGGAGAAGGAAGAGGTGTTTGAAAAG\|TATTGACTTGAAGCTGAAAGAAAAGCCTTA   −                                                                           
  *CTNNB1*                  NM_001904      1 (ch 3, 41241161)                                *PLAG1*        NM_002655              3 (ch 8, 57083748)                    CCCGCGGCGGGAGGAGCCTGTTCCCCTGAG\|ATTGGCCAAAATGGGAAGGATTGGATTCCA   −                                                                           
  *ERBB2*                   NM_001005862   15 (ch 17, 37872192)                              *LTBP4*        NM_001042545           12 (ch 19, 41116438)                  ACACTGCCAACCGGCCAGAGGACGAGTGTG\|ATGTGGACGAGTGCCACCGCGTGCCGCCGC   \+                                                                          
  *MMACHC*                  NM_015506      1 (ch 1, 45966085)                                *BX004987.7*                          (ch 1, 143529235)      97563150       CCTTTTGGCTTCGAGGTTTACCCCTTCCAG\|GTTATATGCAGTACTGAAGAGCAACTTCAG   −                                                                           
  *MMACHC*                  NM_015506      2 (ch 1, 45973222)                                *BX004987.7*                          (ch 1, 143529235)      97556013       GTGGCCTACCATCTGGGCCGTGTTAGAGAG\|GTTATATGCAGTACTGAAGAGCAACTTCAG   −                                                                           
  *PHF3*                    NM_015153      1 (ch 6, 64356700)                                *PTP4A1*       NM_003463              1 (ch 6, 64237724)     118976         ATCCCAATTTCCAGATGCCTTGTTCAACAG\|AGACTTGCTTCAACACCAGGAAGAACATGA   −                                                                           
  *PTER*                    NM_001001484   5 (ch 10, 16547159)                               *MSRB2*        NM_012228              4 (ch 10, 23399171)    6852012        CATGCCTGATGATAACAAAAGAATTAGAAG\|CCTTTCAGTGGGATCTACCTGAATAACAAG   −                                                                           
   Clear                    K2             *DNAH11*                                          NM_003777      79 (ch 7, 21934617)    *RAPGEF5*              NM_012294      7 (ch 7, 22306631)                                               372014     TTATCCTTCTACTTATGGCCTAGCCCAGTG\|GTGCAGAGAGAGCTAGCAGCTGTTATTGCT   −
   Clear                    K3             *PLOD2*                                           NM_000935      1 (ch 3, 145878668)    *CCNYL1*               NM_001142300   4 (ch 2, 208602135)                                                         CTCGGAGAAGCCCTCGAGCATCCCCACAG\|TGTGACCTTAGCAATATATTACCACATAAAG   −
   Clear                    K4             *EPC2*                                            NM_015630      2 (ch 2, 149447942)    *RP11--715D1.1*                       (ch 3, 108828611)                                                           AACAGCCAAAACAGTTCATTCATATTCAGC\|GAGAGAGCTGCCTGCAGAGAGCGTGAGTCC   −
   Clear                    K5             *ATXN7*                                           NM_000333      5 (ch 3, 63938159)     *FHIT*                 NM_001166243   2 (ch 3, 61186339)                                               2751820    TCAAACCGCAGGCATTTCAATCACATTATG\|CTTTGAAGCTCAGGAAAGAAGAGAAATCCA   −
                                           *RP1--45C12.1*                                                   (ch 1, 171137243)      *KIFAP3*               NM_001204514   21 (ch 1, 169890922)                                             1246321    AGATGACAATTCATGTTGTTTTCAGGAAAG\|CCTTGGAATGGATGGCTTTGGCCAACCAGT   −
   Clear                    K6             *POLR2G*                                          NM_002696      2 (ch 11, 62529376)    *CYP1A2*               NM_000761      7 (ch 15, 75047132)                                                         CACCGAGGTGGAGGGGACCTGCACAGGGAA\|AGAGCTGTGGGAGGACCCCTCTGAGTTCCG   \+
   Clear                    K7             *AC010724.1*                                                     (ch 15, 83207631)      *CPEB1*                NM_001079533   8 (ch 15, 83218408)                                              10777      AGAGAAAGGAGAGACAATTATGTTCCTGAG\|GTGCAGGTGATCCCCTGGGTATTAGCCGAC   \+
   Clear                    K8             *RIC8A*                                           NM_021932      1 (ch 11, 211349)      *RP11--34P13.7*                       (ch 1, 92240)                                                               CTCATCTTCCTAGAGAAGCGTTTGCACAAG\|ACCAAACCAATGCAGACCAAACCAATGCAG   −
   Clear                    K9             *SEMA6A*                                          NM_020796      18 (ch 5, 115803279)   *CAMK4*                NM_001744      11 (ch 5, 110825288)                                             4977991    TGTCTTCCCATAATCACCAAGACAAGAAGG\|AGGTCCACCAGGGCAAAATAGAAGCCTTGC   −
   Clear                    K10            *RP11--322M19.1*                                                 (ch 10, 89005872)      *MINPP1*               NM_001178118   2 (ch 10, 89268093)                                              262221     CCTCAGCCTCCAAAGTAGCTGAGACTACAG\|ATATGGAGTTTGGACCTCCAACAGTTAATG   −
   Clear                    K11            *TEX264*                                          NM_001129884   3 (ch 3, 51708578)     *FAM107A*              NM_001076778   1 (ch 3, 58594984)                                               6886406    ATCGCTGTCTACTATGACAACCCCCACATG\|AAAAAGAAATGAAGGCCCAGACACGTTACG   −
   Clear                    K12            *UPF3A*                                           NM_023011      5 (ch 13, 115052104)   *CDC16*                NM_001078645   15 (ch 13, 115027362)                                            24742      AGATGGAGGCGAAGACAAGAGAGCTCATTG\|GTAACAGTTGACAAATGGGAACCTTTGTTG   −
   Clear                    K13            *ASAP1*                                           NM_001247996   29 (ch 8, 131072825)   *ADCY8*                NM_001115      10 (ch 8, 131862049)                                             789224     CCCGTACCACTGCCCAGAAAAATCAATACG\|AGTGATGCCAATGACCATCCAGTTCTCCAT   −
   Clear                    K14            *DCUN1D1*                                         NM_020640      (ch 3, 182679014)      *MCCC1*                NM_020166      18 (ch 3, 182735125)                                             56111      TTGCAAAGAATCCAGGACAAAAAGGATTAG\|GTGTTTGTCAAAGCTGGAGACAAAGTGAAA   −
   Clear                    K15            *CPSF3*                                           NM_016207      7 (ch 2, 9576490)      *ASAP2*                NM_001135191   23 (ch 2, 9533611)                                               42879      GAAGGGCTCAGGAGCTGCTCTTGATTCTAG\|ATCCCCTGACCCCCACGCCGCCCCCACCCG   \+
   Clear                    K16            *ADAMTS2*                                         NM_014244      2 (ch 5, 178770768)    *RP11--798K23.4*                      (ch 5, 178930741)                                                159973     TCTGTGGCGCTCAGCAACTGCGATGGGCTG\|ACCTCTGAATAAGTCGTGGGAGCCCTCGGG   −
   Clear                    K17            *TPPP*                                            NM_007030      2 (ch 5, 677865)       *TERT*                 NM_198253      3 (ch 5, 1282739)                                                604874     TGACGTGGACATCGTCTTCAGCAAGATCAA\|GGGTTGGCTGTGTTCCGGCCGCAGAGCACC   −
  \(B\) Positive controls                                                                                                                                                                                                                                                                                             
   Xp11.2                   K69            *EEF2*                                            NM_001961      1 (ch 19, 3985376)     *ENHO*                 NM_198573      2 (ch 9, 34521854)                                                          TGGGAGAATCCACCGCCATCCGCCACCATG\|GCTCAGGACTGCAGGTAGACATCTCCACTG   −
                                           *NONO*                                            NM_001145408   10 (ch X, 70517788)    *TFE3*                 NM_006521      6 (ch X, 48891766)                                               21626022   GAAGGATTCAAGGGAACCTTCCCTGATGCG\|CTGCCTGTGTCAGGGAATCTGCTTGATGTG   \+
                                           *PARG*                                            NM_003631      8 (ch 10, 51093249)    *BMS1*                 NM_014753      6 (ch 10, 43287075)                                              7806174    GCACTCTGTCTGCCAAATATTTGCACCCAG\|GGTGTCAAGCTGTTCTACCTTTCTGGAATG   \+
                                           *RAGE*                                            NM_014226      1 (ch 14, 102771299)   *EML1*                 NM_001008707   2 (ch 14, 100317190)                                             2454109    TGTCACCGGCTTCCGCATCCAAGATGAAGA\|ATGACAGCGCTTCTGCTGCAAGTAGCATGG   \+
   Xp11.2                   K96            *DPP6*                                            NM_001039350   1 (ch 7, 153584819)    *ACTR3B*               NM_020445      4 (ch 7, 152498706)                                              1086113    AAGACCGCTAAGATGCAGGGGAACGTGATG\|GTATACCAAGCTTGGCTACGCAGGCAACAC   \+
                                           *TFE3*                                            NM_006521      4 (ch X, 48895722)     *RBM10*                NM_001204468   18 (ch X, 47044454)                                              1851268    CTCACCATCGGGTCCAGCTCAGAGAAGGAG\|ATTGCCAAGGACATGGAACGCTGGGCCCG    \+
                                           *RBM10*                                           NM_001204468   17 (ch X, 47041725)    *TFE3*                 NM_006521      5 (ch X, 48895639)                                               1853914    GAGAAGCACAAGACCAAGACAGCTCAACAG\|ATTGATGATGTCATTGATGAGATCATCAGC   \+

Chimeric transcripts (33) included the transcripts (*MMACHC-BX004987.7* and *TFE3-RBM10*) consisting of the same partner gene sets with a different exon boundary or different transcriptional direction, and the transcripts sharing a partner gene, *TFE3*.

National Center for Biotechnology Information Database (Genome Build 37).

The exon boundaries are indicated by a vertical bar. Clear, clear cell renal cell carcinoma; Xp11.2, renal cell carcinoma associated with Xp11.2 translocation; ch, chromosome; +, positive; −, negative.

Previously reported in-frame fusion transcripts including *TFE3* (Table[2](#tbl2){ref-type="table"}B; [@b8]), which are attributable to translocation of the X chromosome, were detected in samples K69 and K96 showing histological findings compatible with Xp11.2 translocation RCC, indicating the reliability of our study. Other than *TFE3* fusion transcripts, three additional transcripts (*EEF2-ENHO, PARG-BMS1*, and *RAGE-EML1*, Table[2](#tbl2){ref-type="table"}B) and one additional transcript (*DPP6-ACTR3B*, Table[2](#tbl2){ref-type="table"}B), which have never been reported in RCCs, were also detected in the K69 and K96, respectively. *NONO-TFE3, PARG-BMS1*, *RAGE-EML1, RBM10-TFE3*, and *DPP6-ACTR3B* transcripts were predicted to generate in-frame chimeric proteins. These observations of additional chimeric transcripts in K69 and K96 were different from the previously reported characteristics of RCCs associated with Xp11.2 translocation \[[@b35]) reported that expression of the *TMED6-COG8* chimeric transcript and higher expression levels of the *EEF1A2* and *CNTN3* genes characterize RCCs associated with Xp11.2 translocation\]. K69 showed grade 3 histology, vascular involvement, and tumor necrosis in surgically resected materials, and the patient developed lymph node metastasis 6 months after surgery, whereas K96 showed grade 3 histology. Such phenotypes, especially those of K69, which are more aggressive than those generally described for RCCs with Xp11.2 translocation ([@b13]), may be attributable to expression of multiple additional chimeric transcripts. Conversely, in three papillary RCCs (K97 to K99) analyzed for comparison, no chimeric transcript was detected.

All 26 chimeric transcripts detected in the initial cohort of clear cell RCCs (Table[2](#tbl2){ref-type="table"}A) have never been reported previously. Even though chimeric transcripts involving the *FHIT* and *TERT* genes have recently been sequenced by The Cancer Genome Atlas (TCGA, [@b45]), the partner gene of *FHIT*, *FAM172A*, and that of *TERT, PDCD6*, listed in TCGA each differed from those (*ATXN7* and *TPPP*) in the present study. Each of the detected chimeric transcripts was expressed in a single clear cell RCC. *ANTXR1-GKN1, ERBB2-LTBP4, POLR2G-CYP1A2, AC010724.1-CPEB1*, and *CPSF3-ASAP2* chimeric transcripts were predicted to generate in-frame chimeric proteins, whereas other chimeric transcripts resulted in a premature stop codon in the 3′-partner gene or were generated in the untranslated regions.

The chimeric transcripts were expressed in 17 clear cell RCCs in the initial cohort \[17/68 (Table[2](#tbl2){ref-type="table"}), 25%\]. Samples K1 and K5 had multiple chimeric transcripts (Table[2](#tbl2){ref-type="table"}). No significant correlation between expression of any of 26 chimeric transcripts and clinicopathological parameters was observed in the initial cohort (Supporting Information Table S4). However, when examined individually, each clear cell RCC with chimeric transcripts showed tumor aggressiveness: e.g., K11 carrying a *TEX264-FAM107A* chimeric transcript showed a type 3 macroscopic configuration and K15 carrying a *CPSF3-ASAP2* chimeric transcript showed a type 3 macroscopic configuration, grade 4 histology, vascular involvement, an invasive growth pattern, and tumor necrosis. Moreover, expression of any of the 26 chimeric transcripts was inversely correlated with the cancer-free survival rate of patients in the initial cohort (the period covered ranged from 42 to 4,783 days \[mean, 2,015 days\]; log-rank test, *P* = 3.19 × 10^−2^; [Fig. 2](#fig02){ref-type="fig"}).

Identification of Genomic Breakpoints in RCCs of the Initial Cohort
-------------------------------------------------------------------

Long-range genomic PCR and Sanger sequencing were performed for 17 clear cell RCCs (K1 to K17) harboring chimeric transcripts using the primers shown in Supporting Information Table S5. Genomic breakpoints for five chimeric transcripts, *POLR2G-CYP1A2, AC010724.1-CPEB1, SEMA6A-CAMK4, ASAP1-ADCY8*, and *CPSF3-ASAP2*, were successfully revealed, but the genomic PCR failed for the other transcripts. The genomic breakpoints for these five chimeric transcripts are summarized in Table[3](#tbl3){ref-type="table"}.

###### 

Genomic Breakpoints of Chimeric Transcripts

  Sample   Genomic breakpoints[a](#tf3-1){ref-type="table-fn"}   Flanking sequences[b](#tf3-2){ref-type="table-fn"}                                           
  -------- ----------------------------------------------------- ---------------------------------------------------- ----------- ---------- ---- ----------- ----------------------------------------------------------------
  K6       *POLR2G*                                              11                                                   62530558    *CYP1A2*   15   75045983    TAGTCTCTCGGAAGATCTGGGTTGGGTTCT\|GAGAATTGCTTGAACTCTGGAGGTAGAGGC
  K7       *AC010724.1*                                          15                                                   83207075    *CPEB1*    15   83219352    GAGATTATTGAAGTAGATCCTGACACTAAG\|GAAATTGGCTCCTCTCTTGTAACTTCTGCC
  K9       *SEMA6A*                                              5                                                    115796806   *CAMK4*    5    110823275   CGTAAGAAATTTGGTACATAAGCTGGTATT\|TTAATCCAATTCATCCAAATTATTCTATCG
  K13      *ASAP1*                                               8                                                    131070249   *ADCY8*    8    131862252   GGCAGACAACGATGACGAGCTCACATTCAT\|TGCAAAGTTTCTCAATAGAGAGAGTGCTCT
  K15      *CPSF3*                                               2                                                    9578689     *ASAP2*    2    9532071     ACCCTGTCACCCAGGCTGGAGTGTGGTGGC\|ACAATCATGGCTCACTGCAGCCTCCAACTC

National Center for Biotechnology Information Database (Genome Build 37).

The genomic breakpoints are indicated by a vertical bar.

Levels of mRNA Expression for the Genes Involved in Chimeric Transcripts
------------------------------------------------------------------------

The levels of mRNA expression for 20 representative partner genes involved in chimeric transcripts in the initial cohort were quantitatively examined in 26 paired T and N samples in the second cohort. The probes and PCR primer sets used are shown in Supporting Information Table S6.

The levels of mRNA expression for the *MMACHC, PTER, EPC2, ATXN7, FHIT, KIFAP3, CPEB1, MINPP1, TEX264, FAM107A*, *UPF3A, CDC16, MCCC1, CPSF3*, and *ASAP2* genes were significantly reduced in T samples relative to the corresponding N samples ([Fig. 1](#fig01){ref-type="fig"}, Mann--Whitney *U* test*, P* = 3.38 × 10^−12^, *P* = 9.04 × 10^−7^, *P* = 8.08 × 10^−3^, *P* = 6.21 × 10^−4^, *P* = 2.71 × 10^−11^, *P* = 9.46 × 10^−4^, *P* = 2.18 × 10^−5^, *P* = 1.03 × 10^−2^, *P* = 2.47 × 10^−9^, *P* = 9.90 × 10^−5^, *P* = 2.53 × 10^−3^, *P* = 1.89 × 10^−4^, *P* = 1.62 × 10^−5^, *P* = 1.77 × 10^−5^, and *P* = 7.17 × 10^−9^, respectively). The levels of mRNA expression for the *MMACHC, PTER, EPC2, ATXN7, FHIT, KIFAP3, CPEB1, TEX264, FAM107A, CDC16, CPSF3*, and *ASAP2* genes in T samples in the second cohort were significantly correlated with clinicopathological parameters reflecting tumor aggressiveness, such as invasive macroscopic configuration, higher histological grades, vascular involvement, invasive growth pattern, tumor necrosis, renal pelvic invasion, distant metastasis, and higher TNM stages (Table[4](#tbl4){ref-type="table"}). Moreover, mRNA levels for the *ATXN7* (*P* = 1.96 × 10^−3^), *KIFAP3* (*P* = 4.72 × 10^−2^*), FAM107A* (*P* = 6.14 × 10^−3^), and *UPF3A* (*P* = 4.19 × 10^−2^) genes in T samples were inversely correlated with the cancer-free survival rate, whereas those for the *EPC2* (*P* = 4.44 × 10^−2^), *FHIT* (*P* = 3.22 × 10^−2^), *CPEB1* (*P* = 9.45 × 10^−3^), and *ASAP2* (*P* = 2.24 × 10^−2^) genes were inversely correlated with the overall survival rate in the second cohort (the period covered ranged from 88 to 5,207 days \[mean, 3,038 days\], the log-rank test; [Fig. 2](#fig02){ref-type="fig"}).

![Levels of mRNA expression for the partner genes involved in chimeric transcripts in 26 paired samples of tumorous tissue (T) and non-cancerous renal cortex tissue (N) in the second cohort. mRNA expression was analyzed using custom TaqMan Gene Expression Assays on the 7500 Fast Real-Time PCR System (Life Technologies) employing the relative standard curve method. The probes and PCR primer sets used are summarized in Supporting Information Table S6. Experiments were performed in triplicate for each sample-primer set, and the mean value for the three experiments was used as the CT value. All CT values were normalized to that of *GAPDH* in the same sample. Levels of mRNA expression for the *MMACHC, PTER, EPC2, ATXN7, FHIT, KIFAP3, CPEB1, MINPP1, TEX264, FAM107A*, *UPF3A, CDC16, MCCC1, CPSF3*, and *ASAP2* genes were significantly reduced in T samples (shaded column) relative to N samples (white column). Bar, standard deviation.](gcc0053-1018-f1){#fig01}

![Kaplan--Meier survival curves of patients with clear cell RCCs in the initial (A) and second (B) cohorts. (A) Expression of any of 26 chimeric transcripts was inversely correlated with the cancer-free survival rate of patients in the initial cohort (the log-rank test, *P* = 3.19 × 10^−2^). (B) ROC curves were generated for levels of mRNA expression of each partner gene of chimeric transcripts, and the thresholds were set to the top left corner of the graph (data not shown). Using these thresholds, Kaplan--Meier curves were generated. mRNA levels for the *ATXN7* (*P* = 1.96 × 10^−3^), *KIFAP3* (*P* = 4.72 × 10^−2^*), FAM107A* (*P* = 6.14 × 10^−3^), and *UPF3A* (*P* = 4.19 × 10^−2^) genes in T samples were inversely correlated with the cancer-free survival rate of patients who underwent complete resection (*n* = 25), whereas those for the *EPC2* (*P* = 4.44 × 10^−2^), *FHIT* (*P* = 3.22 × 10^−2^), *CPEB1* (*P* = 9.45 × 10^−3^), and *ASAP2* (*P* = 2.24 × 10^−2^) genes were inversely correlated with the overall survival rate of all patients (*n* = 26) in the second cohort.](gcc0053-1018-f2){#fig02}

###### 

Correlations Between Levels of mRNA Expression for Each of the Partner Genes Involved in Chimeric Transcripts in Tumorous Tissue Samples and Clinicopathological Parameters Reflecting Tumor Aggressiveness in the Second Cohort

  Clinicopathological parameters                              Number of tumors   *MMACHC*          *PTER*                                          *EPC2*            *ATXN7*                                                                                                                           
  ----------------------------------------------------------- ------------------ ----------------- ----------------------------------------------- ----------------- ----------------------------------------------- ----------------- ----------------------------------------------- --------------- -----------------------------------------------
  Macroscopic configuration[b](#tf4-2){ref-type="table-fn"}                                                                                                                                                                                                                                            
   Type 1                                                     13                 0.0528 ± 0.0226   1.61 × 10^−2^[c](#tf4-3){ref-type="table-fn"}   0.558 ± 0.557     1.88 × 10^−1^[c](#tf4-3){ref-type="table-fn"}   0.114 ± 0.065     1.23 × 10^−1^[c](#tf4-3){ref-type="table-fn"}   0.125 ± 0.099   2.12 × 10^−1^[c](#tf4-3){ref-type="table-fn"}
   Type 2                                                     5                  0.0250 ± 0.0116   0.324 ± 0.400                                   0.0546 ± 0.0480   0.0598 ± 0.0374                                                                                                                   
   Type 3                                                     8                  0.0384 ± 0.0202   0.277 ± 0.248                                   0.0784 ± 0.0596   0.128 ± 0.099                                                                                                                     
  Histological grades[e](#tf4-5){ref-type="table-fn"}                                                                                                                                                                                                                                                  
   G1                                                         1                  0.086             5.05 × 10^−2^[c](#tf4-3){ref-type="table-fn"}   0.574             1.15 × 10^−1^[c](#tf4-3){ref-type="table-fn"}   0.246             4.65 × 10^−3^[c](#tf4-3){ref-type="table-fn"}   0.228           1.64 × 10^−1^[c](#tf4-3){ref-type="table-fn"}
   G2                                                         6                  0.0443 ± 0.0222   0.530 ± 0.608                                   0.112 ± 0.083     0.134 ± 0.144                                                                                                                     
   G3                                                         11                 0.0489 ± 0.0233   0.498 ± 0.479                                   0.106 ± 0.033     0.124 ± 0.082                                                                                                                     
   G4                                                         8                  0.0285 ± 0.0105   0.232 ± 0.309                                   0.0373 ± 0.0185   0.0696 ± 0.0311                                                                                                                   
  Vascular involvement[f](#tf4-6){ref-type="table-fn"}                                                                                                                                                                                                                                                 
   Negative                                                   13                 0.0533 ± 0.0254   2.56 × 10^−2^[g](#tf4-7){ref-type="table-fn"}   0.571 ± 0.433     8.60 × 10^−3^[g](#tf4-7){ref-type="table-fn"}   0.125 ± 0.067     7.24 × 10^−3^[g](#tf4-7){ref-type="table-fn"}   0.139 ± 0.100   5.01 × 10^−2^[g](#tf4-7){ref-type="table-fn"}
   Positive                                                   13                 0.0327 ± 0.0132   0.282 ± 0.452                                   0.0586 ± 0.0383   0.0876 ± 0.078                                                                                                                    
  Growth pattern[e](#tf4-5){ref-type="table-fn"}                                                                                                                                                                                                                                                       
   Expansive                                                  21                 0.046 ± 0.0239    2.00 × 10^−1^[g](#tf4-7){ref-type="table-fn"}   0.482 ± 0.492     1.57 × 10^−1^[g](#tf4-7){ref-type="table-fn"}   0.0954 ± 0.0659   7.53 × 10^−1^[g](#tf4-7){ref-type="table-fn"}   0.121 ± 0.100   7.05 × 10^−1^[g](#tf4-7){ref-type="table-fn"}
   Infiltrative                                               5                  0.0306 ± 0.0077   0.194 ± 0.129                                   0.0762 ± 0.0541   0.0836 ± 0.035                                                                                                                    
  Tumor necrosis                                                                                                                                                                                                                                                                                       
   Negative                                                   16                 0.0503 ± 0.0242   1.69 × 10^−2^[g](#tf4-7){ref-type="table-fn"}   0.548 ± 0.513     1.44 × 10^−2^[g](#tf4-7){ref-type="table-fn"}   0.120 ± 0.064     7.13 × 10^−4^[g](#tf4-7){ref-type="table-fn"}   0.142 ± 0.106   2.68 × 10^−2^[g](#tf4-7){ref-type="table-fn"}
   Positive                                                   10                 0.0314 ± 0.0134   0.232 ± 0.277                                   0.0472 ± 0.0274   0.0672 ± 0.0281                                                                                                                   
  Renal pelvic invasion                                                                                                                                                                                                                                                                                
   Negative                                                   23                 0.0451 ± 0.0230   1.34 × 10^−1^[g](#tf4-7){ref-type="table-fn"}   0.469 ± 0.471     8.46 × 10^−3^[g](#tf4-7){ref-type="table-fn"}   0.0973 ± 0.0649   1.57 × 10^−1^[g](#tf4-7){ref-type="table-fn"}   0.120 ± 0.095   2.11 × 10^−1^[g](#tf4-7){ref-type="table-fn"}
   Positive                                                   3                  0.0270 ± 0.0030   0.101 ± 0.018                                   0.0487 ± 0.0218   0.0620 ± 0.0265                                                                                                                   
  Distant metastasis                                                                                                                                                                                                                                                                                   
   Negative                                                   24                 0.0450 ± 0.0221   2.46 × 10^−2^[g](#tf4-7){ref-type="table-fn"}   0.413 ± 0.460     4.98 × 10^−1^[g](#tf4-7){ref-type="table-fn"}   0.0974 ± 0.0625   5.54 × 10^−2^[g](#tf4-7){ref-type="table-fn"}   0.120 ± 0.093   3.69 × 10^−2^[g](#tf4-7){ref-type="table-fn"}
   Positive                                                   2                  0.0185 ± 0.0007   0.589 ± 0.572                                   0.0235 ± 0.0021   0.0365 ± 0.0106                                                                                                                   
  Pathological TNM stage[h](#tf4-8){ref-type="table-fn"}                                                                                                                                                                                                                                               
   Stage I                                                    13                 0.0430 ± 0.0166   5.54 × 10^−2^[c](#tf4-3){ref-type="table-fn"}   0.561 ± 0.573     4.69 × 10^−1^[c](#tf4-3){ref-type="table-fn"}   0.104 ± 0.056     1.78 × 10^−1^[c](#tf4-3){ref-type="table-fn"}   0.112 ± 0.095   1.87 × 10^−1^[c](#tf4-3){ref-type="table-fn"}
   Stage II                                                   3                  0.0277 ± 0.0155   0.204 ± 0.232                                   0.0607 ± 0.0503   0.112 ± 0.099                                                                                                                     
   Stage III                                                  8                  0.0549 ± 0.0287   0.251 ± 0.163                                   0.100 ± 0.078     0.135 ± 0.097                                                                                                                     
   Stage IV                                                   2                  0.0185 ± 0.0007   0.589 ± 0.572                                   0.0235 ± 0.0021   0.0365 ± 0.0106                                                                                                                   

  Clinicopathological parameters                              Number of Tumors   *FHIT*            *KIFAP3*                                        *CPEB1*             *TEX264*                                                                                                                            
  ----------------------------------------------------------- ------------------ ----------------- ----------------------------------------------- ------------------- ----------------------------------------------- ------------------- ----------------------------------------------- --------------- -----------------------------------------------
  Macroscopic configuration[b](#tf4-2){ref-type="table-fn"}                                                                                                                                                                                                                                                
   Type 1                                                     13                 0.177 ± 0.125     4.73 × 10^−2^[c](#tf4-3){ref-type="table-fn"}   0.0884 ± 0.0432     3.82 × 10^−2^[c](#tf4-3){ref-type="table-fn"}   0.00369 ± 0.00572   3.31 × 10^−1^[c](#tf4-3){ref-type="table-fn"}   0.155 ± 0.111   9.22 × 10^−1^[c](#tf4-3){ref-type="table-fn"}
   Type 2                                                     5                  0.0782 ± 0.0187   0.0362 ± 0.0222                                 0.0058 ± 0.0102     0.142 ± 0.104                                                                                                                       
   Type 3                                                     8                  0.100 ± 0.069     0.0675 ± 0.0345                                 0.0084 ± 0.0113     0.143 ± 0.086                                                                                                                       
  Histological grades[e](#tf4-5){ref-type="table-fn"}                                                                                                                                                                                                                                                      
   G1                                                         1                  0.280             6.62 × 10^−3^[c](#tf4-3){ref-type="table-fn"}   0.118               1.18 × 10^−1^[c](#tf4-3){ref-type="table-fn"}   0.004               4.23 × 10^−2^[c](#tf4-3){ref-type="table-fn"}   0.148           9.75 × 10^−2^[c](#tf4-3){ref-type="table-fn"}
   G2                                                         6                  0.211 ± 0.172     0.0862 ± 0.0535                                 0.00383 ± 0.00722   0.233 ± 0.154                                                                                                                       
   G3                                                         11                 0.130 ± 0.044     0.0718 ± 0.0259                                 0.00173 ± 0.00168   0.142 ± 0.068                                                                                                                       
   G4                                                         8                  0.0631 ± 0.0308   0.0556 ± 0.0481                                 0.0123 ± 0.0119     0.0955 ± 0.0427                                                                                                                     
  Vascular involvement[f](#tf4-6){ref-type="table-fn"}                                                                                                                                                                                                                                                     
   Negative                                                   13                 0.178 ± 0.126     1.20 × 10^−2^[g](#tf4-7){ref-type="table-fn"}   0.0839 ± 0.0384     5.68 × 10^−2^[g](#tf4-7){ref-type="table-fn"}   0.00492 ± 0.00742   1.00[g](#tf4-7){ref-type="table-fn"}            0.155 ± 0.112   6.50 × 10^−1^[g](#tf4-7){ref-type="table-fn"}
   Positive                                                   13                 0.0898 ± 0.0503   0.0599 ± 0.0421                                 0.00615 ± 0.00978   0.143 ± 0.088                                                                                                                       
  Growth pattern[e](#tf4-5){ref-type="table-fn"}                                                                                                                                                                                                                                                           
   Expansive                                                  21                 0.150 ± 0.109     4.09 × 10^−2^[g](#tf4-7){ref-type="table-fn"}   0.0752 ± 0.0446     5.69 × 10^−1^[g](#tf4-7){ref-type="table-fn"}   0.00433 ± 0.00664   1.05 × 10^−1^[g](#tf4-7){ref-type="table-fn"}   0.158 ± 0.104   3.40 × 10^−1^[g](#tf4-7){ref-type="table-fn"}
   Infiltrative                                               5                  0.0660 ± 0.0410   0.0580 ± 0.0207                                 0.0106 ± 0.0139     0.112 ± 0.066                                                                                                                       
  Tumor necrosis                                                                                                                                                                                                                                                                                           
   Negative                                                   16                 0.174 ± 0.114     5.55 × 10^−4^[g](#tf4-7){ref-type="table-fn"}   0.0820 ± 0.0381     3.09 × 10^−2^[g](#tf4-7){ref-type="table-fn"}   0.00275 ± 0.00449   4.08 × 10^−2^[g](#tf4-7){ref-type="table-fn"}   0.183 ± 0.110   6.05 × 10^−3^[g](#tf4-7){ref-type="table-fn"}
   Positive                                                   10                 0.0699 ± 0.0316   0.0558 ± 0.0431                                 0.0100 ± 0.0115     0.0943 ± 0.0395                                                                                                                     
  Renal pelvic invasion                                                                                                                                                                                                                                                                                    
   Negative                                                   23                 0.143 ± 0.107     1.34 × 10^−1^[g](#tf4-7){ref-type="table-fn"}   0.0763 ± 0.0420     6.38 × 10^−2^[g](#tf4-7){ref-type="table-fn"}   0.00461 ± 0.00639   5.94 × 10^−1^[g](#tf4-7){ref-type="table-fn"}   0.156 ± 0.103   3.12 × 10^−1^[g](#tf4-7){ref-type="table-fn"}
   Positive                                                   3                  0.0643 ± 0.0397   0.0380 ± 0.0044                                 0.0127 ± 0.0193     0.0922 ± 0.0222                                                                                                                     
  Distant metastasis                                                                                                                                                                                                                                                                                       
   Negative                                                   24                 0.141 ± 0.106     5.54 × 10^−2^[g](#tf4-7){ref-type="table-fn"}   0.0755 ± 0.0409     3.69 × 10^−2^[g](#tf4-7){ref-type="table-fn"}   0.00458 ± 0.00790   5.54 × 10^−2^[g](#tf4-7){ref-type="table-fn"}   0.156 ± 0.100   5.54 × 10^−2^[g](#tf4-7){ref-type="table-fn"}
   Positive                                                   2                  0.0520 ± 0.0014   0.0285 ± 0.0078                                 0.0170 ± 0.0099     0.0638 ± 0.0021                                                                                                                     
  Pathological TNM stage[h](#tf4-8){ref-type="table-fn"}                                                                                                                                                                                                                                                   
   Stage I                                                    13                 0.161 ± 0.124     1.40 × 10^−1^[c](#tf4-3){ref-type="table-fn"}   0.0730 ± 0.0375     7.75 × 10^−2^[c](#tf4-3){ref-type="table-fn"}   0.00300 ± 0.00478   1.15 × 10^−1^[c](#tf4-3){ref-type="table-fn"}   0.153 ± 0.111   2.26 × 10^−1^[c](#tf4-3){ref-type="table-fn"}
   Stage II                                                   3                  0.0893 ± 0.0302   0.0400 ± 0.0271                                 0.00100 ± 0.00100   0.195 ± 0.116                                                                                                                       
   Stage III                                                  8                  0.127 ± 0.090     0.0930 ± 0.0446                                 0.0085 ± 0.0117     0.147 ± 0.083                                                                                                                       
   Stage IV                                                   2                  0.0520 ± 0.0014   0.0285 ± 0.0078                                 0.0170 ± 0.0099     0.0638 ± 0.0021                                                                                                                     

  Clinicopathological parameters                              Number of Tumors   *FAM107A*         *CDC16*                                         *CPSF3*           *ASAP2*                                                                                                                             
  ----------------------------------------------------------- ------------------ ----------------- ----------------------------------------------- ----------------- ----------------------------------------------- ----------------- ----------------------------------------------- ----------------- -----------------------------------------------
  Macroscopic configuration[b](#tf4-2){ref-type="table-fn"}                                                                                                                                                                                                                                              
   Type 1                                                     13                 0.312 ± 0.184     5.51 × 10^−2^[c](#tf4-3){ref-type="table-fn"}   0.113 ± 0.054     1.35 × 10^−1^[c](#tf4-3){ref-type="table-fn"}   0.0476 ± 0.0255   2.78 × 10^−1^[c](#tf4-3){ref-type="table-fn"}   0.0455 ± 0.0346   1.85 × 10^−1^[c](#tf4-3){ref-type="table-fn"}
   Type 2                                                     5                  0.0986 ± 0.0779   0.0584 ± 0.0377                                 0.0260 ± 0.0151   0.0218 ± 0.0191                                                                                                                     
   Type 3                                                     8                  0.203 ± 0.242     0.0926 ± 0.0753                                 0.0465 ± 0.0286   0.0250 ± 0.0227                                                                                                                     
  Histological grades[e](#tf4-5){ref-type="table-fn"}                                                                                                                                                                                                                                                    
   G1                                                         1                  0.685             2.14 × 10^−2^[c](#tf4-3){ref-type="table-fn"}   0.172             1.28 × 10^−2^[c](#tf4-3){ref-type="table-fn"}   0.0613            1.30 × 10^−1^[c](#tf4-3){ref-type="table-fn"}   0.112             1.93 × 10^−2^[c](#tf4-3){ref-type="table-fn"}
   G2                                                         6                  0.209 ± 0.140     0.113 ± 0.083                                   0.0575 ± 0.0335   0.0399 ± 0.0320                                                                                                                     
   G3                                                         11                 0.313 ± 0.197     0.116 ± 0.049                                   0.0464 ± 0.0236   0.0411 ± 0.0252                                                                                                                     
   G4                                                         8                  0.100 ± 0.129     0.0475 ± 0.0206                                 0.0256 ± 0.0118   0.0122 ± 0.0068                                                                                                                     
  Vascular involvement[f](#tf4-6){ref-type="table-fn"}                                                                                                                                                                                                                                                   
   Negative                                                   13                 0.258 ± 0.182     3.11 × 10^−1^[g](#tf4-7){ref-type="table-fn"}   0.123 ± 0.063     2.56 × 10^−2^[g](#tf4-7){ref-type="table-fn"}   0.0518 ± 0.0271   1.13 × 10^−1^[g](#tf4-7){ref-type="table-fn"}   0.0508 ± 0.030    7.95 × 10^−4^[g](#tf4-7){ref-type="table-fn"}
   Positive                                                   13                 0.217 ± 0.226     0.0696 ± 0.0458                                 0.0344 ± 0.0214   0.0185 ± 0.0203                                                                                                                     
  Growth pattern[e](#tf4-5){ref-type="table-fn"}                                                                                                                                                                                                                                                         
   Expansive                                                  21                 0.255 ± 0.211     4.47 × 10^−1^[g](#tf4-7){ref-type="table-fn"}   0.0975 ± 0.0608   8.01 × 10^−1^[g](#tf4-7){ref-type="table-fn"}   0.0437 ± 0.0263   9.00 × 10^−1^[g](#tf4-7){ref-type="table-fn"}   0.0372 ± 0.0316   4.09 × 10^−1^[g](#tf4-7){ref-type="table-fn"}
   Infiltrative                                               5                  0.166 ± 0.159     0.0914 ± 0.0662                                 0.0409 ± 0.0246   0.0240 ± 0.0211                                                                                                                     
  Tumor necrosis                                                                                                                                                                                                                                                                                         
   Negative                                                   16                 0.317 ± 0.205     2.24 × 10^−3^[g](#tf4-7){ref-type="table-fn"}   0.121 ± 0.063     5.02 × 10^−3^[g](#tf4-7){ref-type="table-fn"}   0.0535 ± 0.0266   1.44 × 10^−2^[g](#tf4-7){ref-type="table-fn"}   0.0475 ± 0.0317   2.77 × 10^−3^[g](#tf4-7){ref-type="table-fn"}
   Positive                                                   10                 0.110 ± 0.117     0.0567 ± 0.0278                                 0.0266 ± 0.0115   0.0142 ± 0.0086                                                                                                                     
  Renal pelvic invasion                                                                                                                                                                                                                                                                                  
   Negative                                                   23                 0.259 ± 0.205     7.85 × 10^−2^[g](#tf4-7){ref-type="table-fn"}   0.100 ± 0.063     3.52 × 10^−1^[g](#tf4-7){ref-type="table-fn"}   0.0453 ± 0.0263   3.95 × 10^−1^[g](#tf4-7){ref-type="table-fn"}   0.0368 ± 0.0313   4.42 × 10^−1^[g](#tf4-7){ref-type="table-fn"}
   Positive                                                   3                  0.0726 ± 0.0602   0.0650 ± 0.0128                                 0.0263 ± 0.0073   0.0179 ± 0.0058                                                                                                                     
  Distant metastasis                                                                                                                                                                                                                                                                                     
   Negative                                                   24                 0.256 ± 0.199     5.54 × 10^−2^[g](#tf4-7){ref-type="table-fn"}   0.102 ± 0.059     2.46 × 10^−2^[g](#tf4-7){ref-type="table-fn"}   0.0457 ± 0.0249   1.23 × 10^−2^[g](#tf4-7){ref-type="table-fn"}   0.0363 ± 0.0307   3.94 × 10^−1^[g](#tf4-7){ref-type="table-fn"}
   Positive                                                   2                  0.0165 ± 0.0030   0.0245 ± 0.0007                                 0.0125 ± 0.0019   0.0151 ± 0.0005                                                                                                                     
  Pathological TNM stage[h](#tf4-8){ref-type="table-fn"}                                                                                                                                                                                                                                                 
   Stage I                                                    13                 0.246 ± 0.152     2.72 × 10^−1^[c](#tf4-3){ref-type="table-fn"}   0.109 ± 0.053     4.59 × 10^−2^[c](#tf4-3){ref-type="table-fn"}   0.0445 ± 0.0279   9.67 × 10^−2^[c](#tf4-3){ref-type="table-fn"}   0.0404 ± 0.0279   1.86 × 10^−1^[c](#tf4-3){ref-type="table-fn"}
   Stage II                                                   3                  0.209 ± 0.167     0.0513 ± 0.0307                                 0.0324 ± 0.0170   0.0103 ± 0.0082                                                                                                                     
   Stage III                                                  8                  0.290 ± 0.284     0.110 ± 0.071                                   0.0526 ± 0.0220   0.0394 ± 0.0376                                                                                                                     
   Stage IV                                                   2                  0.0165 ± 0.0030   0.0245 ± 0.0007                                 0.0125 ± 0.0019   0.0151 ± 0.0005                                                                                                                     

Average mRNA levels/GAPDH ± standard deviation.

Macroscopic configuration was evaluated on the basis of previously described criteria ([@b2]).

Kruskal--Wallis test. *P* values of \< 0.05 are underlined.

All the tumors were graded on the basis of previously described criteria ([@b14]).

If the tumor showed heterogeneity, the most aggressive features of the tumor were described.

The presence or absence of vascular involvement was examined microscopically on slides stained with hematoxylin-eosin and elastica van Gieson.

Mann--Whitney *U* test. *P* values of \<0.05 are underlined.

All the tumors were classified according to the pathological Tumor-Node-Metastasis classification ([@b40]). Although no significant correlation between expression of any of the 26 chimeric transcripts and clinicopathological parameters was observed in the initial cohort (Supporting Information, Table S4), downregulation of mRNA levels for each of the partner genes did show significant correlations with the above clinicopathological parameters in the second cohort.

DISCUSSION
==========

To comprehensively explore chimeric transcripts in clear cell RCCs, whole transcriptome analysis was performed using tissue specimens. The significance of generation of chimeric transcripts has not been fully elucidated in adult solid tumors other than well-studied exceptions, such as sarcomas and adenocarcinomas of the prostate and the lung. Although previous reports of fusion events involving the *ALK* gene based on FISH and immunohistochemistry have been restricted to nonclear cell RCCs ([@b42]), when comprehensively explored using next-generation sequencing technology, chimeric transcripts were detected in 25% (17/68) of the clear cell RCCs. In some RCCs (K1 and K5), multiple chimeric transcripts were observed. Moreover, the genomic breakpoints revealed for five chimeric transcripts in clear cell RCCs indicate that such transcripts have actually arisen through genomic rearrangement. Gene fusion events may thus play a greater role in renal carcinogenesis than previously anticipated. Conversely, mechanisms other than genomic rearrangements ([@b50]), e.g., trans-splicing ([@b26]), may generate chimeric transcripts in which genomic breakpoints are not revealed.

The WHO classification defines RCC associated with Xp11.2 translocation, which involves *TFE3* fusion, as a distinct subtype ([@b13]). Diagnosis of RCC associated with Xp11.2 translocation depends on detection of *TFE3* protein overexpression using immunohistochemistry or detection of gene fusion using FISH and/or RT-PCR analysis ([@b16]; [@b36]). The procedure for final diagnosis of RCC associated with Xp11.2 translocation differs from that for other RCC subtypes, such as clear cell RCC, papillary RCC, and chromophobe RCC, which generally can be diagnosed on the basis of histological observation. As RCC associated with Xp11.2 translocation and other RCCs were lumped into the same category as the RCC subtypes, the final diagnosis of RCC subtypes could not be made based solely on conventional histological examination of surgically resected or biopsy specimens. As the present comprehensive study demonstrated multiple chimeric transcripts in various RCCs, it seems that the use of Xp11.2 translocation as the only criterion for defining a distinct subtype of RCC may not be a rational approach. The classification of RCC subtypes should therefore be revised after a more comprehensive appraisal of correlations between histological features and genetic background.

All 26 chimeric transcripts detected in the initial cohort were novel chimeric transcripts that have never been reported previously in RCCs. However, only five of them were predicted to generate in-frame chimeric proteins in clear cell RCCs. Expression microarray analysis did not necessarily suggest prominent overexpression of in-frame chimeric transcripts in the initial cohort (data not shown). Moreover, in-frame chimeric transcripts observed in clear cell RCCs do not necessarily result in constitutive activation of protein kinases, which frequently cause addiction for gene fusion events. Conversely, many genes for which reduced expression and/or tumor suppressive function have been reported in human cancers were included in chimeric transcripts observed in the initial cohort. Therefore, we examined the levels of mRNA expression for 20 representative genes involved in chimeric transcripts in the second cohort (Supporting Information Table S6) and revealed significantly reduced mRNA expression of the *MMACHC, PTER, EPC2, ATXN7, FHIT, KIFAP3, CPEB1, MINPP1, TEX264, FAM107A*, *UPF3A, CDC16, MCCC1, CPSF3*, and *ASAP2* genes in T samples in the second cohort ([Fig. 1](#fig01){ref-type="fig"}).

It has been reported that reduced expression of the *MMACHC* gene, which participates in intracellular trafficking of cobalamin, can result in increased tumorigenicity and methionine dependence of cancer cells ([@b29]). Although its implication in human cancers has been unclear, the *PTER* gene was first cloned as a rat homolog of bacterial phosphotriesterase, and its expression in the normal proximal tubules of the kidney has been reported ([@b11]). Single nucleotide polymorphism (SNP) of the *EPC2* gene has been reported to be associated with response to gemcitabine in human cancer cell lines ([@b19]). SNP of the *ATXN7* gene, which encodes a subunit of the GCN5 histone acetyltransferase-containing coactivator complex ([@b18]), is reportedly associated with susceptibility to breast cancer (Milne et al., in press). The fragile *FHIT* gene, encompassing the chromosomal fragile site *FRA3B*, is a target of DNA damage-induced cancer initiation and progression through modulation of genomic stability ([@b20]). KIFAP3 is colocalized with KIF3, which participates in subcellular transport of several cancer-related proteins including beta-catenin and cadherins ([@b44]). Down regulation of *CPEB1*, which participates in the regulation of mRNA translation and processing of the 3′ untranslated region ([@b4]), has been reported in human cancers ([@b5]). As has been reported for the *PTEN* gene, somatic mutation and germline variants of the *MINPP1* gene, located in proximity to *PTEN* in 10q23.3, have been reported in patients with follicular thyroid tumors ([@b15]). *FAM107A* was first identified in a commonly deleted region in 3p21 in RCCs ([@b49]), and transfection of this gene induces growth suppression and apoptosis of FAM107A-negative cancer cell lines ([@b49]; [@b27]). UPF3A is a crucial factor of nonsense-mediated decay, an RNA decay pathway that downregulates aberrant mRNAs ([@b7]). CDC16 is a component of the Anaphase Promoting Complex/Cyclosome (APC/C), which governs cell cycle progression and has crucial functions in maintaining genomic integrity and tumorigenesis ([@b52]). Genetic imbalance at the *MCCC1* gene locus has recently been reported in clinical specimens of oral squamous cell carcinoma ([@b37]). *CPSF3* is required for site-specific endonucleolytic cleavage and poly (A) addition ([@b21]) and directly interacts with ([@b53]) tumor suppressor gene product CSR1 ([@b51]). The src homology 3 domain of the paxillin-binding protein ([@b23]; [@b9]), *ASAP2*, directly interacts with the SAMP repeat region of the *APC* tumor suppressor gene ([@b31]).

Although the *TEX264* gene has been simply identified as one of the protein-encoding open reading frames deposited in a database ([@b24]), the above characteristics of each of the partner genes suggest that down-regulation of the *MMACHC, PTER, EPC2, ATXN7, FHIT, KIFAP3, CPEB1, MINPP1, FAM107A*, *UPF3A, CDC16, MCCC1, CPSF3*, and *ASAP2* genes may participate in renal carcinogenesis. Moreover, the levels of mRNA expression for many of the partner genes in T samples were significantly correlated with the clinicopathological aggressiveness of RCCs (Table[4](#tbl4){ref-type="table"}) and were inversely correlated with the cancer-free and/or overall survival rates of patients with clear cell RCCs ([Fig. 2](#fig02){ref-type="fig"}), indicating that such reduced expression may continue to play a role in multistage malignant progression during renal carcinogenesis.

Even if the same chimeric transcripts detected in the initial cohorts had been expressed in the second cohort, quantitative RT-PCR analysis for each partner gene would not have evaluated chimeric transcripts lacking target exons (Supporting Information Table S6). Therefore, to reveal the presence or absence of the same chimeric transcripts detected in the initial cohort, RT-PCR analysis using total RNA samples and the primer sets indicated in Supporting Information Table S3 and long-range PCR analysis using genomic DNA samples and the primer sets described in Supporting Information Table S5 were performed in the second cohort. These analyses did not detect the same chimeric transcripts in the second cohort (data not shown). As all detected chimeric transcripts were expressed only in a single clear cell RCC in the initial cohort, it is possible that the same chimeric transcripts may have been absent in the second cohort. Downregulation of mRNA levels for each of the genes described in [Figure 1](#fig01){ref-type="fig"} in the second cohort would have been attributable to mechanisms other than expression of chimeric transcripts, such as gene deletion, DNA methylation status around the promoter regions and/or alterations in the expression levels, and accessibility of transcription factors. In fact, silencing of the *MMACHC* ([@b29]) and *CPEB1* ([@b5]) genes due to DNA methylation, and gene deletion and DNA methylation of *FHIT* ([@b20]), have been reported in human cancers. However, further studies are needed to reveal the mechanisms responsible for downregulation of each of the partner genes in the second cohort.

Conversely, it is feasible that dysfunction of each partner gene is induced by generation of chimeric transcripts in the initial cohort of clear cell RCCs, as such mechanisms of tumor suppressor gene functional impairment have been reported in adult malignancies such as acute myeloid leukemia ([@b32]). Even though prominent overexpression and/or constitutive activation of growth factors and/or protein kinases due to gene fusion events is rare, generation of chimeric transcripts may participate in renal carcinogenesis through dysfunction of tumor-related genes.

Supporting Information
======================

Additional Supporting Information may be found in the online version of this article.
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